> Details

Katibah, George; Ohol, Yamini; Bucher, Cyril; Adusumilli, Lavanya; Kaveri, Deepika; Robles, Omar; Sun, Michael; Cho, Cynthia; Milestone, Heather; Ames, Rachel; Jacobson, Scott; Nebalasca, Dan; Gomez- Guagua, Justy; Sanchez, Jerick; Grandcolas, Molly; Wong, Steve; Brovarney, Martin; Ramana, Chandru; Zaw, Thant; Nguyen, Lan; Tivitmahaisoon, Parcharee; Ng, Andrew; Ma, Anqi; Gomez, Blanca; [...]

Abstract 1646: Development of small-molecule HPK1 inhibitors to unleash tumor-specific T cell responses

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Abstract 1646: Development of small-molecule HPK1 inhibitors to unleash tumor-specific T cell responses
  • Contributor: Katibah, George; Ohol, Yamini; Bucher, Cyril; Adusumilli, Lavanya; Kaveri, Deepika; Robles, Omar; Sun, Michael; Cho, Cynthia; Milestone, Heather; Ames, Rachel; Jacobson, Scott; Nebalasca, Dan; Gomez- Guagua, Justy; Sanchez, Jerick; Grandcolas, Molly; Wong, Steve; Brovarney, Martin; Ramana, Chandru; Zaw, Thant; Nguyen, Lan; Tivitmahaisoon, Parcharee; Ng, Andrew; Ma, Anqi; Gomez, Blanca; [...]
  • imprint: American Association for Cancer Research (AACR), 2021
  • Published in: Cancer Research
  • Language: English
  • DOI: 10.1158/1538-7445.am2021-1646
  • ISSN: 0008-5472; 1538-7445
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Hematopoietic progenitor kinase 1 (HPK1) is an intracellular protein kinase that negatively regulates T cell signaling and proliferation. Upon T cell receptor (TCR) activation, active HPK1 phosphorylates the adaptor protein SLP76 in the TCR complex, recruiting the negative regulator 14-3-3 and targeting components of the TCR signaling complex for degradation. HPK1 thus limits the TCR signaling important for mounting an effective immune response against tumor cells. We are employing structure-guided drug design to develop potent small-molecule inhibitors of HPK1. Our compounds potently inhibit HPK1 in biochemical assays, reduce levels of phosphorylated SLP76 and concomitantly increase IL-2 production by Jurkat T cells. Importantly, our HPK1 inhibitors enhance cytokine production by human and mouse primary T cells above that observed with TCR activation alone. Treatment of mice with orally available HPK1 inhibitors results in increased activation of antigen-specific CD8+ T cells in vivo and decreased tumor growth as single agent and in combination with clinically relevant checkpoint inhibitor antibodies. Our work confirms the importance of HPK1 for T cell function and supports HPK1 as a promising next generation immuno-oncology target.</jats:p> <jats:p>Citation Format: George Katibah, Yamini Ohol, Cyril Bucher, Lavanya Adusumilli, Deepika Kaveri, Omar Robles, Michael Sun, Cynthia Cho, Heather Milestone, Rachel Ames, Scott Jacobson, Dan Nebalasca, Justy Gomez- Guagua, Jerick Sanchez, Molly Grandcolas, Steve Wong, Martin Brovarney, Chandru Ramana, Thant Zaw, Lan Nguyen, Parcharee Tivitmahaisoon, Andrew Ng, Anqi Ma, Blanca Gomez, Michelle Ko, Paul Leger, Jeffrey Jackson, Grant Shibuya, Anton Shakhmin, Delia Bradford, Mengshu Xu, Mikhail Zibinsky, Daniel Poon, David Wustrow, Paul Kassner, Dirk Brockstedt. Development of small-molecule HPK1 inhibitors to unleash tumor-specific T cell responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1646.</jats:p>
  • Access State: Open Access